Topic: Payment & Reimbursement
-
The “Netflix Model” of Financing Hepatitis C Treatment
Read More
-
Cardiovascular Drugs Not Price Aligned with Value in US
Read More
-
Perspective on National Coverage Analysis of CAR-T Therapies
Read More
-
Spending On Prescription Drugs In The US: Where Does All The Money Go?
Read More
-
DPL responds to HHS Blueprint (May 16, 2018)
Read More
-
Impact of President Trump’s Proposed 340B Hospital Eligibility Threshold
Read More
-
Does the 6% in Medicare Part B Drug Reimbursement Affect Prescribing?
Read More
-
Money-Back Guarantees for Expensive Drugs: Wolf’s Clothing but a Sheep Underneath
Read More
-
Outcomes-Based Drug Contracts Do Not Move Us Closer to Value
Read More
-
Copay Assistance: The Epipen Example
Read More